Formations of, Acquisitions by, and Mergers of Bank Holding Companies, 37157-37158 [2021-14997]
Download as PDF
<![CDATA[
lotter on DSK11XQN23PROD with NOTICES1
Federal Register / Vol. 86, No. 132 / Wednesday, July 14, 2021 / Notices
joint procurement and joint negotiation
authority.
Proposed Effective Date: 6/30/2021.
Location: https://www2.fmc.gov/
FMC.Agreements.Web/Public/
AgreementHistory/317.
Agreement No.: 012390–001.
Agreement Name: Siem Car Carriers
AS/Liberty Global Logistics LLC Space
Charter Agreement.
Parties: Siem Car Carriers AS and
Liberty Global Logistics LLC.
Filing Party: Ashley Craig; Venable
LLP.
Synopsis: The amendment updates
Article 5.3 of the Agreement to remove
joint procurement and joint negotiation
authority.
Proposed Effective Date: 6/30/2021.
Location: https://www2.fmc.gov/
FMC.Agreements.Web/Public/
AgreementHistory/1006.
Agreement No.: 201363.
Agreement Name: Ho¨egh Autoliners/
National Shipping Company of Saudi
Arabia (Bahri) Space Charter
Agreement.
Parties: Hoegh Autoliners AS and The
National Shipping Company of Saudi
Arabia d.b.a. Bahri AS.
Filing Party: Wayne Rohde; Cozen
O’Connor.
Synopsis: The Agreement authorizes
the parties to charter space to/from one
another in all U.S. trades worldwide.
Proposed Effective Date: 8/15/2021.
Location: https://www2.fmc.gov/
FMC.Agreements.Web/Public/
AgreementHistory/47520.
Agreement No.: 201348–001.
Agreement Name: APL/Swire Guam,
Saipan—S. Korea, Japan Slot Charter
Agreement.
Parties: American President Lines,
LLC and The China Navigation Co. Pte.
Ltd. d/b/a Swire Shipping.
Filing Party: Patricia O’Neill;
American President Lines, LLC.
Synopsis: The Amendment revises
Article 5.1 to add Hakata, Japan as a
port call under the Agreement.
Proposed Effective Date: 7/2/2021.
Location: https://www2.fmc.gov/
FMC.Agreements.Web/Public/
AgreementHistory/34502.
Agreement No.: 012426–006.
Agreement Name: The OCEAN
Alliance Agreement.
Parties: COSCO SHIPPING Lines Co.,
Ltd.; CMA CGM S.A. and APL Co. Pte.
Ltd. (acting as a single party); Evergreen
Marine Corporation (Taiwan) Ltd.; and
Orient Overseas Container Line Limited.
Filing Party: Robert Magovern; Cozen
O’Connor.
Synopsis: The Amendment revises
Article 2 to add Evergreen Marine (Asia)
Pte. Ltd. as a sub-party to the
Agreement.
VerDate Sep<11>2014
17:49 Jul 13, 2021
Jkt 253001
Proposed Effective Date: 8/20/2021.
Location: https://www2.fmc.gov/
FMC.Agreements.Web/Public/
AgreementHistory/1214.
Agreement No.: 201351–001.
Agreement Name: Foundation Carrier
Agreement.
Parties: Maersk A/S; CMA CGM S.A.
MSC Mediterranean Shipping Company
S.A.; Hapag-Lloyd AG; and Ocean
Network Express Pte Ltd.
Filing Party: Wayne Rohde; Cozen
O’Connor.
Synopsis: The amendment adds
Hapag-Lloyd Aktiengesellschaft and
Ocean Network Express Pte Ltd. as
parties to the Agreement, and makes
corresponding adjustments in Articles
5.1(b), 5.3(c), and 6.4 of the Agreement.
Proposed Effective Date: 8/21/2021.
Location: https://www2.fmc.gov/
FMC.Agreements.Web/Public/
AgreementHistory/36502.
Agreement No.: 201364.
Agreement Name: Agreement
Between the City of Los Angeles, the
City of Long Beach, Portcheck, LLC, and
Marine Terminal Operators.
Parties: Portcheck, LLC; The City of
Long Beach Harbor Department; The
City of Long Beach Harbor Department;
APM Terminals Pacific LLC; Fenix
Marine Services, Ltd.; Everport
Terminal Services, Inc.; International
Transportation Service, LLC; LBCT LLC;
Total Terminals International, LLC;
West Basin Container Terminal LLC;
Pacific Maritime Services, LLC; SSAT
(Pier A), LLC; Yusen Terminals LLC;
Trapac LLC, and SSA Terminals, LLC.
Filing Party: Wayne Rohde; Cozen
O’Connor.
Synopsis: The Agreement sets forth
the terms and conditions under which
PortCheck LLC and the marine terminal
operators will provide certain services
to the ports as provided for in tariffs
published by the ports. These services
relate to the collection of a clean truck
fee in accordance with provisions to be
published in the ports’ respective tariffs.
Proposed Effective Date: 8/20/2021.
Location: https://www2.fmc.gov/
FMC.Agreements.Web/Public/
AgreementHistory/47525.
Agreement No.: 012214–001.
Agreement Name: Glovis/’’K’’ Line
Space Charter Agreement.
Parties: Kawasaki Kisen Kaisha, Ltd.
and Hyundai Glovis Co., Ltd.
Filing Party: John Meade, ‘‘K’’ Line
America, Inc.
Synopsis: The amendment eliminates
the parties’ authority to jointly negotiate
for covered services under the
Agreement and updates the address for
Hyundai Glovis.
Proposed Effective Date: 7/1/2021.
PO 00000
Frm 00044
Fmt 4703
Sfmt 4703
37157
Location: https://www2.fmc.gov/
FMC.Agreements.Web/Public/
AgreementHistory/265.
Agreement No.: 201365–002.
Agreement Name: Volkswagen
Konzernlogistik GmbH & Co. OHG/NYK
Line Space Charter Agreement.
Parties: Volkswagen Konzernlogistik
GmbH & Co. OHG and Nippon Yusen
Kaisha.
Filing Party: Kristen Chung; NYK
Group Americas Inc.
Synopsis: The amendment removes
all authority to jointly negotiate or
procure terminal services in the United
States.
Proposed Effective Date: 7/2/2021.
Location: https://www2.fmc.gov/
FMC.Agreements.Web/Public/
AgreementHistory/60.
Agreement No.: 012386–001.
Agreement Name: K Line/NYK Space
Charter Agreement.
Parties: Kawasaki Kisen Kaisha, Ltd.
and Nippon Yusen Kaisha.
Filing Party: Kristen Chung; NYK
Group Americas Inc.
Synopsis: This amendment removes
all authority to jointly negotiate or
procure terminal services in the United
States.
Proposed Effective Date: 7/2/2021.
Location: https://www2.fmc.gov/
FMC.Agreements.Web/Public/
AgreementHistory/1002.
Dated: July 8, 2021.
Rachel E. Dickon,
Secretary.
[FR Doc. 2021–14926 Filed 7–13–21; 8:45 am]
BILLING CODE 6730–02–P
FEDERAL RESERVE SYSTEM
Formations of, Acquisitions by, and
Mergers of Bank Holding Companies
The companies listed in this notice
have applied to the Board for approval,
pursuant to the Bank Holding Company
Act of 1956 (12 U.S.C. 1841 et seq.)
(BHC Act), Regulation Y (12 CFR part
225), and all other applicable statutes
and regulations to become a bank
holding company and/or to acquire the
assets or the ownership of, control of, or
the power to vote shares of a bank or
bank holding company and all of the
banks and nonbanking companies
owned by the bank holding company,
including the companies listed below.
The public portions of the
applications listed below, as well as
other related filings required by the
Board, if any, are available for
immediate inspection at the Federal
Reserve Bank(s) indicated below and at
the offices of the Board of Governors.
E:\FR\FM\14JYN1.SGM
14JYN1
37158
Federal Register / Vol. 86, No. 132 / Wednesday, July 14, 2021 / Notices
This information may also be obtained
on an expedited basis, upon request, by
contacting the appropriate Federal
Reserve Bank and from the Board’s
Freedom of Information Office at
https://www.federalreserve.gov/foia/
request.htm. Interested persons may
express their views in writing on the
standards enumerated in the BHC Act
(12 U.S.C. 1842(c)).
Comments regarding each of these
applications must be received at the
Reserve Bank indicated or the offices of
the Board of Governors, Ann E.
Misback, Secretary of the Board, 20th
Street and Constitution Avenue NW,
Washington, DC 20551–0001, not later
than August 13, 2021.
A. Federal Reserve Bank of Boston
(Prabal Chakrabarti, Senior Vice
President) 600 Atlantic Avenue, Boston,
Massachusetts 02210–2204. Comments
can also be sent electronically to
BOS.SRC.Applications.Comments@
bos.frb.org:
1. Independent Bank Corp.,
(‘‘Independent’’) through its subsidiary,
Bradford Merger Sub Inc., both of
Rockland, Massachusetts; to merge with
Meridian Bancorp, Inc., Peabody,
Massachusetts (‘‘Meridian’’), with
Meridian as the survivor, and thereby
indirectly acquire East Boston Savings
Bank, Boston, Massachusetts.
Immediately after, Meridian to merge
with Independent, with Independent as
the survivor, and East Boston Savings
Bank to merge with and into Rockland
Trust, Rockland, Massachusetts, a
wholly owned subsidiary bank of
Independent, with Rockland Trust as
the surviving bank.
Board of Governors of the Federal Reserve
System, July 9, 2021.
Michele Taylor Fennell,
Deputy Associate Secretary of the Board.
entitled, ‘‘Agency Information
Collection Activities: Submission for
OMB Review; Comment Request.’’ That
notice invited public comments on three
separate information collection requests
specific to document identifiers: CMS–
10215, CMS–10249, and CMS–10341.
Through the publication of this
document, we are withdrawing the
portion of the notice requesting public
comment on the information collection
request titled ‘‘Section 1115
Demonstration Projects Regulations at
42 CFR 431.408, 431.412, 431.420,
431.424, and 431.428.’’ Form number
CMS–10341 (OMB control number
0938–1162). The withdrawn
information collection request will be
replaced by another 30-day notice in
July or August of this year.
DATES: For CMS–10215 and CMS–
10249, the original comment period for
the notice that published on July 9,
2021, remains in effect and ends August
9, 2021.
SUPPLEMENTARY INFORMATION: In FR
document, 2021–14671, published on
July 9, 2021 (86 FR 36281), we are
withdrawing item 3 ‘‘Section 1115
Demonstration Projects Regulations at
42 CFR 431.408, 431.412, 431.420,
431.424, and 431.428’’ which posted on
page 36282.
Dated: July 9, 2021.
William N. Parham, III,
Director, Paperwork Reduction Staff, Office
of Strategic Operations and Regulatory
Affairs.
[FR Doc. 2021–15005 Filed 7–13–21; 8:45 am]
BILLING CODE 4120–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[FR Doc. 2021–14997 Filed 7–13–21; 8:45 am]
BILLING CODE P
[Docket No. FDA–2021–P–0191]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Determination That STROMECTOL
(Ivermectin) Tablets, 6 Milligrams,
Were Not Withdrawn From Sale for
Reasons of Safety or Effectiveness
Centers for Medicare & Medicaid
Services
AGENCY:
[Document Identifier: CMS–10341]
ACTION:
lotter on DSK11XQN23PROD with NOTICES1
Agency Information Collection
Activities: Submission for OMB
Review; Comment Request
Centers for Medicare &
Medicaid Services, HHS.
ACTION: Notice; partial withdrawal.
On Friday, July 9, 2021, the
Centers for Medicare & Medicaid
Services (CMS) published a notice
VerDate Sep<11>2014
17:49 Jul 13, 2021
Jkt 253001
Notice.
The Food and Drug
Administration (FDA or Agency) has
determined that STROMECTOL
(ivermectin) tablets, 6 milligrams (mg),
were not withdrawn from sale for
reasons of safety or effectiveness. This
determination will allow FDA to
approve abbreviated new drug
applications (ANDAs) for
STROMECTOL (ivermectin) tablets, 6
SUMMARY:
AGENCY:
SUMMARY:
Food and Drug Administration,
HHS.
PO 00000
Frm 00045
Fmt 4703
Sfmt 4703
mg, if all other legal and regulatory
requirements are met.
FOR FURTHER INFORMATION CONTACT:
Christopher Koepke, Center for Drug
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Silver Spring, MD
20993–0002, 301–796–3600,
Christopher.Koepke@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: In 1984,
Congress enacted the Drug Price
Competition and Patent Term
Restoration Act of 1984 (Pub. L. 98–417)
(the 1984 amendments), which
authorized the approval of duplicate
versions of drug products under an
ANDA procedure. ANDA applicants
must, with certain exceptions, show that
the drug for which they are seeking
approval contains the same active
ingredient in the same strength and
dosage form as the ‘‘listed drug,’’ which
is a version of the drug that was
previously approved. ANDA applicants
do not have to repeat the extensive
clinical testing otherwise necessary to
gain approval of a new drug application
(NDA).
The 1984 amendments include what
is now section 505(j)(7) of the Federal
Food, Drug, and Cosmetic Act (21 U.S.C.
355(j)(7)), which requires FDA to
publish a list of all approved drugs.
FDA publishes this list as part of the
‘‘Approved Drug Products With
Therapeutic Equivalence Evaluations,’’
which is known generally as the
‘‘Orange Book.’’ Under FDA regulations,
drugs are removed from the list if the
Agency withdraws or suspends
approval of the drug’s NDA or ANDA
for reasons of safety or effectiveness or
if FDA determines that the listed drug
was withdrawn from sale for reasons of
safety or effectiveness (21 CFR 314.162).
A person may petition the Agency to
determine, or the Agency may
determine on its own initiative, whether
a listed drug was withdrawn from sale
for reasons of safety or effectiveness.
This determination may be made at any
time after the drug has been withdrawn
from sale, but must be made prior to
approving an ANDA that refers to the
listed drug (§ 314.161 (21 CFR 314.161)).
FDA may not approve an ANDA that
does not refer to a listed drug.
STROMECTOL (ivermectin) tablets, 6
mg, are the subject of NDA 050742, held
by Merck Sharp and Dohme Corp., and
initially approved on November 22,
1996. STROMECTOL is indicated for
strongyloidiasis of the intestinal tract
and onchocerciasis.
In a letter dated September 14, 2007,
Merck and Co., Inc. notified FDA that
STROMECTOL (ivermectin) tablets, 6
mg, were being discontinued, and FDA
E:\FR\FM\14JYN1.SGM
14JYN1
]]>Agencies
[Federal Register Volume 86, Number 132 (Wednesday, July 14, 2021)]
[Notices]
[Pages 37157-37158]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-14997]
=======================================================================
-----------------------------------------------------------------------
FEDERAL RESERVE SYSTEM
Formations of, Acquisitions by, and Mergers of Bank Holding
Companies
The companies listed in this notice have applied to the Board for
approval, pursuant to the Bank Holding Company Act of 1956 (12 U.S.C.
1841 et seq.) (BHC Act), Regulation Y (12 CFR part 225), and all other
applicable statutes and regulations to become a bank holding company
and/or to acquire the assets or the ownership of, control of, or the
power to vote shares of a bank or bank holding company and all of the
banks and nonbanking companies owned by the bank holding company,
including the companies listed below.
The public portions of the applications listed below, as well as
other related filings required by the Board, if any, are available for
immediate inspection at the Federal Reserve Bank(s) indicated below and
at the offices of the Board of Governors.
[[Page 37158]]
This information may also be obtained on an expedited basis, upon
request, by contacting the appropriate Federal Reserve Bank and from
the Board's Freedom of Information Office at https://www.federalreserve.gov/foia/request.htm. Interested persons may express
their views in writing on the standards enumerated in the BHC Act (12
U.S.C. 1842(c)).
Comments regarding each of these applications must be received at
the Reserve Bank indicated or the offices of the Board of Governors,
Ann E. Misback, Secretary of the Board, 20th Street and Constitution
Avenue NW, Washington, DC 20551-0001, not later than August 13, 2021.
A. Federal Reserve Bank of Boston (Prabal Chakrabarti, Senior Vice
President) 600 Atlantic Avenue, Boston, Massachusetts 02210-2204.
Comments can also be sent electronically to
[email protected]:
1. Independent Bank Corp., (``Independent'') through its
subsidiary, Bradford Merger Sub Inc., both of Rockland, Massachusetts;
to merge with Meridian Bancorp, Inc., Peabody, Massachusetts
(``Meridian''), with Meridian as the survivor, and thereby indirectly
acquire East Boston Savings Bank, Boston, Massachusetts. Immediately
after, Meridian to merge with Independent, with Independent as the
survivor, and East Boston Savings Bank to merge with and into Rockland
Trust, Rockland, Massachusetts, a wholly owned subsidiary bank of
Independent, with Rockland Trust as the surviving bank.
Board of Governors of the Federal Reserve System, July 9, 2021.
Michele Taylor Fennell,
Deputy Associate Secretary of the Board.
[FR Doc. 2021-14997 Filed 7-13-21; 8:45 am]
BILLING CODE P
